OUR OFFER

Beacon® package
(mAbs generation)

- Antigen or mRNA immunization
- Beacon® screen
- Hundreds of hits recovery, wave of 50-100 hits production at 100 µg scale
- Characterization/validation of hits (Affinity, EC_{50})

mAb bioproduction / engineering
(1 to 500 mg scale)

- Naked mAbs, bispecific (all common formats)
- ADC (linker payloads validated in the clinics)
- Industry standard quality controls (SDS, SEC, MS)

Pre-CMC

- Humanisation (molecular modeling and CDR grafting)
- Biophysical characterization
  - *In silico* "hotspots" sequence analysis
  - Formulation and concentration testing
  - Biochemistry, thermal and pH stability studies
  - *Ex-vivo* stability study in serum or PK ADC

In vitro pharmacology

- Direct cytotoxicity test (incl. CDX and PDX-derived *vitro* models)
- Immune modulation/functional tests (ADCC, ADCP, CDC...)
- Generation of transfectants

In vivo immuno-pharmacology

- Efficacy in syngeneic models
- Immunophenotyping
- Efficacy in xenogeneic models (CDX)

OUR TRACK RECORD

- **Transferred to clinical development:** naked mAbs CD39 (Astra-Zeneca) and CD73 (Innate Pharma)
- **Transferred to regulatory driven development:** naked mAb Siglec (Innate Pharma), Bispecific NK cell engager (Sanofi)
- **Close to regulatory driven development:** 3 ADCs : MICA, NKp46 (Innate Pharma, and undisclosed)
- **More than 100 immunizations programs** (tools and drug candidates)
- **~20 target validation programs:** 16 naked, 3 ADCs, 1 bispecific
- **13 publications in peer reviewed journals:** Cell, Cell report, Immunity…
- **1 new tool for bispecifics:** a human CD3e KI mice model

FOCUS ON: Nectin 4 ADC
Emergence Therapeutics

- Generation, selection and humanization of candidates
- Conjugation with several linker payloads to 300 mg level for PK and efficacy in mice (in house) and pre-tox in monkey (outsourced)
- Selection of final candidate/linker payload, transfer to CDMO
- This work was the basis of ETX 87 million fundraising in 2022

Emergence Therapeutics was acquired by Eli Lilly in 2023

OUR BUSINESS MODELS

Fee-for-service collaboration or **FTE-based partnership**

Either way, wo do not retain any IP rights.

LET'S WORK TOGETHER

Tell us about your project at contact@mimabs.com

Accelerating antibody discovery for difficult targets using mRNA immunization and BEACON® single cell technology

Manuel PELE, Marie-Claire PHELIPOT, Frédérique LEMBO, Laura CHLADNI, Alice AYMARD, Eric CHABROL, Laurent POUYET, François ROMAGNE

mAbs
ANTIBODIES FOR MEDICINE

The highway to mAb drug candidates

Abstract

Despite demonstrated efficiency in antibody generation, classical immunization strategies and subsequent hybridoma generation often face strong limitations when it comes to complex targets like GPCRs or tetraspanins. We have developed innovative approaches combining mRNA immunization and Bruker Beacon® single cell screening platform to provide unique opportunities to dramatically speed up antibody discovery against such challenging targets.

MImAbs ANTIBODIES FOR MEDICINE

Workflow



Figure 1: Representative workflow of an antibody generation campaign using Bruker Beacon®-based single B cell screening

- Compared to the widely used hybridoma approach, larger collections of B cells are screened at higher throughput using the single cell approach.

mRNA Immunization

Current challenges in immunization:
- Possible issues in recombinant protein production
- Poor immunogenicity / cross-reactivity



Figure 2: Serum titration after immunization with cells, mRNA or a combination of cells & mRNA injections.

- Immunization with mRNA alone or in combination with cells helps improve immune response levels.
- mRNA from different species can be used to increase cross-reactivity.

«On-chip» Functional Assays

Functional sequential/multiplexed assays



Figure 3: "On-chip" functional assays examples.
Screening can be performed on beads (upper panel ; IgG specific, peptide- or protein-coated beads) or on target expressing-cells (lower panel).

- Sequential or multiplexed functional assays can be performed to refine candidate selection prior to hit export, antibody sequencing, production and further "off-chip" validation.
- Validated B cells are individually exported to recover corresponding antibody sequencing for further production and characterization.

GPCR Campaign Example

A)

Mice Immunization (nb of mice)	Nb of campaigns	Screened colonies/clones	Positive clones
Cells only (>10)	4 (hybridoma, historical data)	> 5,000	0
mRNA only (6)	1 (hybridoma)	2,963	**0**
Cells + mRNA (6)	1 (hybridoma)	2,266	**1**
mRNA only or cells + mRNA *	**1 (Beacon®)**	**> 35,000**	**26 unique mAbs**



Figure 4: Table A recapitulates data from all campaigns performed on the targeted GPCR (* remaining mice from hybridoma campaign). Graphs B and C illustrate comparative EC50 on human-target expressing cells for antibodies generated from different immunization strategies and graph D highlights cross-reactive clones against cynomolgus monkey ortholog.

- Antibody discovery was strikingly improved using the combination of mRNA immunization and single B cell screening. No difference in affinity could be observed between clones resulting from mixed immunization or mRNA only and 1 cross-reactive clones was obtained from each group.

Therapeutic mAb Candidate Roadmap



Conclusion

Using innovative approaches like RNA immunization and single B cell screening, MImAbs has developed the know-how to tackle the challenge of antibody generation against difficult targets like GPRCs, ion channels or other complex proteins with multiple transmembrane domains. Combined with multiple functional assays upon candidate selection and possible use of ATX-Gx™ humanized mice, time to therapeutic candidate antibody delivery can now be significantly shortened.